Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL1154468

NCCS(=O)(=O)O.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 1/20 0.33
ADRB1 known ✓ P08588 1/20 0.33
ADRA2A known ✓ P08913 1/20 0.33
ADRA2B known ✓ P18089 1/20 0.33
ADRA2C known ✓ P18825 1/20 0.33
SLC6A2 known ✓ P23975 1/20 0.33
ADRA1D known ✓ P25100 1/20 0.33
BLM P54132 3/20 0.64
LMNA P02545 2/20 0.64
SLC6A6 P31641 1/20 0.64
CYP2C19 P33261 1/20 0.64
APP P05067 1/20 0.46
TSHR P16473 3/20 0.46
PMP22 Q01453 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GABRR1 P24046 2/20 0.33
PDE4A P27815 2/20 0.33
PTGS1 P23219 1/20 0.33
NFKB1 P19838 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Taurine SCHEMBL27979344 0.84 LMNA (0.61) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL30443868 0.84 LMNA (0.61) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL4449607 0.83 LMNA (0.82) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL27979203 0.83 LMNA (0.58) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL27814625 0.80 LMNA (0.78) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL3799348 0.80 LMNA (0.61) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL23068 0.80
Taurine SCHEMBL30179154 0.80
Taurine SCHEMBL30191395 0.80
Taurine SCHEMBL42632 0.80 BLM (1.00) BLMLMNASLC6A6CYP2C19APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090304620-A1 HAIR TREATMENT PRODUCTS COMPRISING POLYMERS HENKEL AG & CO. KGAA (DE) 2009-12-10 US claimed
EP-1942877-A1 ORGANOLEPTICALLY ACCEPTABLE IBUPROFEN ORAL DOSAGE FORMULATIONS, METHODS OF MAKING AND USING THE SAME Teikoku Pharma USA, Inc. (US) 2008-07-16 EP claimed
WO-2007055887-A1 ORGANOLEPTICALLY ACCEPTABLE IBUPROFEN ORAL DOSAGE FORMULATIONS, METHODS OF MAKING AND USING THE SAME TEIKOKU PHARMA USA, INC. (US) 2007-05-18 WO claimed
US-20070098789-A1 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same TEIKOKU PHARMA USA, INC. 2007-05-03 US claimed
US-10722439-B2 Hair care products HENKEL AG & CO. KGAA (DE) 2020-07-28 US disclosed
US-20200170912-A1 COMPOSITION FOR THE CARE OF HUMAN HAIR HENKEL AG & CO. KGAA (DE) 2020-06-04 US disclosed
US-10328007-B2 Hair straightening with carbocisteine HENKEL AG & CO. KGAA (DE) 2019-06-25 US disclosed
US-20190021968-A1 HAIR CARE PRODUCTS HENKEL AG & CO. KGAA (DE) 2019-01-24 US disclosed
US-20160296441-A1 CONDITIONER FOR KERATIN FIBERS HAVING A SILICONE SUBSTITUTE HENKEL AG & CO. KGAA (DE) 2016-10-13 US disclosed
US-9456976-B2 Hair treatment compositions comprising selected UV filters and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines HENKEL AG & CO. KGAA (DE) 2016-10-04 US disclosed
US-20160263000-A1 HAIR STRAIGHTENING WITH CARBOCISTEINE HENKEL AG & CO. KGAA (DE) 2016-09-15 US disclosed
US-9248087-B2 Anti-dandruff hair care products with selective active ingredients and a cationic keratin HENKEL AG & CO. KGAA (DE) 2016-02-02 US disclosed
US-20130125914-A1 HAIR-CONDITIONING COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2013-05-23 US disclosed
US-20120204895-A1 HAIR TREATMENT AGENTS COMPRISING POLYQUATERNIUM-72 HENKEL AG & CO. KGAA (DE) 2012-08-16 US disclosed
US-20120171149-A1 AGENTS FOR TREATING KERATIN FIBERS, CONTAINING DIMETHYLSILANOL HYALURONATES AND GLYCEROL HENKEL AG & CO. KGAA (DE) 2012-07-05 US disclosed
US-20120121529-A1 HAIR CONDITIONERS COMPRISING SELECTED CATIONIC SILICONES AND DIMETHICONE HENKEL AG & CO. KGAA (DE) 2012-05-17 US disclosed
US-20120114586-A1 HAIR CONDITIONERS COMPRISING SELECTED CATIONIC SILICONES AND A B SERIES VITAMIN HENKEL AG & CO. KGAA (DE) 2012-05-10 US disclosed
US-20110268684-A1 HAIR CONDITIONERS COMPRISING IMIDAZOLINES AND ESTER OILS HENKEL AG & CO. KGAA (DE) 2011-11-03 US disclosed
US-20110033407-A1 Hair Treatment Means With Cloudberry Extract HENKEL AG & CO. KGAA (DE) 2011-02-10 US disclosed
US-20090304620-A1 HAIR TREATMENT PRODUCTS COMPRISING POLYMERS HENKEL AG & CO. KGAA (DE) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10722439-B2 Hair care products ACMSD, ARG1, NACA ADRB2 3191/4885ADRB1 3342/4885ADRA2A 2943/4885
US-20120204895-A1 HAIR TREATMENT AGENTS COMPRISING POLYQUATERNIUM-72 HTT, AAAS, HNMT ADRB2 2386/4885ADRB1 2917/4885ADRA2A 2541/4885
US-20120171149-A1 AGENTS FOR TREATING KERATIN FIBERS, CONTAINING DIMETHYLSILANOL HYALURONATES AND GLYCEROL KRT18, CD44, DSG1 ADRB2 4220/4885ADRB1 4225/4885ADRA2A 3483/4885
US-20110268684-A1 HAIR CONDITIONERS COMPRISING IMIDAZOLINES AND ESTER OILS PLIN3, PLIN5, FABP4 ADRB2 2950/4885ADRB1 3229/4885ADRA2A 3326/4885
US-20090304620-A1 HAIR TREATMENT PRODUCTS COMPRISING POLYMERS ASS1, SRM, COL1A1 ADRB2 4142/4885ADRB1 4152/4885ADRA2A 2838/4885
US-20120121529-A1 HAIR CONDITIONERS COMPRISING SELECTED CATIONIC SILICONES AND DIMETHICONE KRT18, DNER, DSC1 ADRB2 4562/4885ADRB1 4518/4885ADRA2A 4581/4885
US-20070098789-A1 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same CYP2D6, CYP2A6, CYP2C9 ADRB2 2328/4885ADRB1 2568/4885ADRA2A 1506/4885
US-20110033407-A1 Hair Treatment Means With Cloudberry Extract KRT18, TUBB8, TUBB6 ADRB2 3950/4885ADRB1 3821/4885ADRA2A 4173/4885
US-20190021968-A1 HAIR CARE PRODUCTS ACMSD, ARG1, NACA ADRB2 3019/4885ADRB1 3111/4885ADRA2A 2785/4885
US-10328007-B2 Hair straightening with carbocisteine KRT18, PRKDC, PRKACG ADRB2 4292/4885ADRB1 4528/4885ADRA2A 4335/4885
US-20120114586-A1 HAIR CONDITIONERS COMPRISING SELECTED CATIONIC SILICONES AND A B SERIES VITAMIN KRT18, PROC, BTD ADRB2 4179/4885ADRB1 4217/4885ADRA2A 4315/4885
US-20160296441-A1 CONDITIONER FOR KERATIN FIBERS HAVING A SILICONE SUBSTITUTE KRT18, CUTA, DNER ADRB2 4162/4885ADRB1 4145/4885ADRA2A 4388/4885
US-20130125914-A1 HAIR-CONDITIONING COMPOSITIONS SHH, HDAC10, NR5A1 ADRB2 1332/4885ADRB1 1346/4885ADRA2A 999/4885
US-20200170912-A1 COMPOSITION FOR THE CARE OF HUMAN HAIR POLR1C, KRT18, SLC27A1 ADRB2 2079/4885ADRB1 2240/4885ADRA2A 2828/4885
US-20160263000-A1 HAIR STRAIGHTENING WITH CARBOCISTEINE KRT18, PRKDC, PRKACG ADRB2 4292/4885ADRB1 4528/4885ADRA2A 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.